A study on treatment of locally advanced squamous cell carcinoma of head and neck with radiation along with cisplatin or gefitinib

Simple item page
dc.contributor.authorSharma, Shyamen_US
dc.contributor.authorBiswas, Linkonen_US
dc.contributor.authorRoy, Arabindaen_US
dc.contributor.authorBiswas, Koustaven_US
dc.contributor.authorBose, Rajdeepen_US
dc.contributor.authorMandal, Srikrishnaen_US
dc.date.accessioned2023-06-17T08:52:12Z
dc.date.available2023-06-17T08:52:12Z
dc.date.issued2022-12
dc.description.abstractBackground: Cisplatin based Concurrent chemo-radiation (CTRT) is the corner stone for treatment of locally advanced head and neck carcinoma. Epidermal growth factor receptor(EGFR) expression by squamous cell carcinoma which is associated with cancer development and progression,leads to emergence of anti-EGFR agents as a therapeutic option. In this study we compare cisplatin based CTRT against gefitinib based CTRT in terms of disease control and acute toxicity profile. Material and Methods: Stage III and IV squamous cell carcinoma of Head and neck region (excluding nasopharynx) were randomised into two groups. Control group received conventionally fractionated radiotherapy of 66Gy in 33fractions, over six and half weeks with concurrent weekly cisplatin. Study group received same dose of radiation with concurrent daily oral Gefitinib. All patients were followed up weekly during the treatment and then 6-8 weeks after completion of treatment and thereafter 3 monthly. Results: Overall response rate (complete response + partial response) was comparable for both arms (75% vs 76.2%, p value-0.881). Radiation with cisplatin was associated with significantly higher skin (28.6% vs 15%,p value-0.037) and mucosal (23.8% vs 5%,p-value-0.047) toxicities. Gefitinib containing arm showed significantly higher grade 3 diarrhoea (10% vs 0%, p-value-0.01) and skin rash (6% vs 0%, p -value-<0.001).With a median follow-up of 12.5 months Disease free survival (DFS) was not significantly different between the arms(12 vs 13 months). Conclusion: Gefitinib based CTRT is non-inferior to cisplatin based CTRT for the treatment of locally advanced head and neck carcinoma with acceptable toxicity profile.en_US
dc.identifier.affiliationsDepartment of Radiotherapy, Nilratan Sircar Medical College and Hospital, 138, A J C Bose Road, Kolkata, India.en_US
dc.identifier.affiliationsdepartment Of Radiotherapy, Raiganj Government Medical College And Hospital, B.C.Roy, Pranabananda Sarani, Raiganj, West Bengal, India.en_US
dc.identifier.citationSharma Shyam, Biswas Linkon, Roy Arabinda, Biswas Koustav, Bose Rajdeep, Mandal Srikrishna. A study on treatment of locally advanced squamous cell carcinoma of head and neck with radiation along with cisplatin or gefitinib. Medica Innovatica. 2022 Dec; 11(2): 1-6en_US
dc.identifier.issn2278-7526
dc.identifier.issn2320-7582
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/216965
dc.languageenen_US
dc.publisherB.V.V. Sangha’s S. Nijalingappa Medical Collegeen_US
dc.relation.issuenumber2en_US
dc.relation.volume11en_US
dc.source.urihttps://www.medicainnovatica.org/medica_dec_22/1%20Linkon%20Biswas.pdfen_US
dc.subjectLocally advanced Head and Neck carcinomaen_US
dc.subjectconcurrent chemo-radiationen_US
dc.subjectCisplatinen_US
dc.subjectGefitinib.en_US
dc.titleA study on treatment of locally advanced squamous cell carcinoma of head and neck with radiation along with cisplatin or gefitiniben_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
MI2022v11n2p1.pdf
Size:
177.33 KB
Format:
Adobe Portable Document Format
Download
Collections
Medica Innovatica